An Overview of Various Cancer Treatments of Melanoma and its Diagnosis
Main Article Content
Exposure to harmful radiation, chemicals or genetic factors result in various types of cancers formation and development. Melanoma is one of the dangerous skin cancers. If its not diagnosed early and kept not treated at the right time it can even lead to the death. The direct effect of this skin cancer melanoma is on the melanin pigment producing melanocytes which can be a result of exposure to the Ultraviolet rays and time after time the melanocytes becomes cancerous. Nowadays in the current cancer treatments there are so many possibilities to reduce the spreading of skin cancer cells if they diagnosed earlier. Some of the cancer treatments such as chemotherapy result in many side effects and eventually has the beneficial pharmacological effects on the cancerous cells. Effective treatment and therapies of melanoma involves the chemotherapy, immunotherapy, targeted therapy with combination of transduction inhibitors, regional and systematic chemotherapies, radiation and palliative therapies and final effective removal of cancerous cells by surgery. Immuno-regulatory gates are induced by the human body to spontaneously suppress immune reactions and prevent the immune system from damaging normal cells. Tumor cells can’t able to block the immune system when checkpoint blockers are used. Even so, but the survival rate of those affected population is still low and the main reason of the occurrence of this skin cancer is still unclear. This article reviews an overview of diagnosis, pathophysiology and various cancer treatment used in present days and its impact on the melanoma.
Siegal R, Miller KD, Jemal A. Cancer statistics, 2012. Ca Cancer J Clin. 2014 Jan;64(1):9-29.
Isola AL, Eddy K, Chen S. Biology, therapy and implications of tumor exosomes in the progression of melanoma. Cancers. 2016 Dec 9;8(12):110.
Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of melanoma. Exon Publications. 2017 Nov 30:3-22.
White LP. Studies on melanoma: sex and survival in human melanoma. New England Journal of Medicine. 1959 Apr 16;260(16):789-97.
Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Edwards MJ, Chagpar AB. Gender-related differences in outcome for melanoma patients. Annals of surgery. 2006 May;243(5):693.
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo. 2014 Nov 1;28(6):1005-11.
Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. Journal of the American Academy of Dermatology. 1987 Sep 1;17(3):459-68.
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016 Jun;534(7605):47-54.
Aversa J, Song M, Shimazu T, Inoue M, Charvat H, Yamaji T, Sawada N, Pfeiffer RM, Karimi P, Dawsey SM, Rabkin CS. Prediagnostic circulating inflammation biomarkers and esophageal squamous cell carcinoma: A case–cohort study in Japan. International journal of cancer. 2020 Aug 1;147(3):686-91.
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, French Familial Melanoma Study Group, Bénard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Human molecular genetics. 1998 Feb 1;7(2):209-16.
Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma research. 2012 Apr;22(2):114.
Lee C, Collichio F, Ollila D, Moschos S. Historical review of melanoma treatment and outcomes. Clinics in dermatology. 2013 Mar 1;31(2):141-7.
Vickers NJ. Animal communication: when i’m calling you, will you answer too?. Current biology. 2017 Jul 24;27(14):R713-5.
Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Current oncology reports. 2012 Oct;14(5):449-57.
Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiology Biomarkers & Prevention. 2006 Dec;15(12):2526-32.
Read J, Wadt KA, Hayward NK. Melanoma genetics. Journal of medical genetics. 2016 Jan 1;53(1):1-4.
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D. TERT promoter mutations in familial and sporadic melanoma. Science. 2013 Feb 22;339(6122):959-61.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine. 2011 Jun 30;364(26):2507-16.
Colllins B, LeonBarnes Jr E, Abernethy J. Oral malignant melanoma. J Clin Oncol. 2005;55:74-108.
Schwämmle V, Sidoli S, Ruminowicz C, Wu X, Lee CF, Helin K, Jensen ON. Systems level analysis of histone H3 post-translational modifications (PTMs) reveals features of PTM crosstalk in chromatin regulation. Molecular & Cellular Proteomics. 2016 Aug 1;15(8):2715-29.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial.
Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nature immunology. 2001 Sep;2(9):882-8.
Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. InSeminars in oncology 2015 Aug 1 (Vol. 42, No. 4, pp. 539-548). WB Saunders.
Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25hi Foxp3+ regulatory T cells in cancer patients. Blood. 2006 Mar 15;107(6):2409-14.
Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2–regulated Fas-mediated T cell apoptosis. Immunity. 1998 May 1;8(5):615-23.
Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2–induced vascular leak. Clinical Cancer Research. 2007 Apr 1;13(7):2115-20.
Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. Journal of Immunotherapy. 2011 Jun 1;34(5):419-27.
McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. Journal of Clinical Oncology. 2008 May 1;26(13):2178-85.
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of clinical oncology. 1995 Mar;13(3):688-96.
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of clinical oncology. 1999 Jul;17(7):2105-.
Mitchison DA. Basic mechanisms of chemotherapy. Chest. 1979 Dec 1;76(6):771-80.
Services ST, Hospital B. A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore: Second report. Tubercle. 1974 Dec 1;55(4):251-60.
Velu S, Andrews RH, Angel JH, Devadatta S, Fox W, Jacob PG, Nair CN, Ramakrishnan CV. Streptomycin plus pyrazinamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli, following previous chemotherapy. Tubercle. 1961 Jan 1;42(2):136-47.
Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull. Int. Union Tuberc.. 1978;53(1):5-12.
Dickinson JM, Mitchison DA. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle. 1970 Dec 1;51(4):389-96.
Guo N, Minas G, Synowsky SA, Dunne MR, Ahmed H, McShane R, Bhardwaj A, Donlon NE, Lorton C, O'Sullivan J, Reynolds JV. Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS. Journal of Proteomics. 2022 Aug 30;266:104684.
Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thrombosis research. 2006 Jan 1;118(5):555-68.
Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer treatment reviews. 2008 Nov 1;34(7):603-13.
Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer research. 2012 Apr 1;32(4):1379-86.
Laviano A, Rossi Fanelli F. Toxicity in chemotherapy—when less is more. New England Journal of Medicine. 2012 Jun 14;366(24):2319-20.
Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. Journal of hematology & oncology. 2017 Dec;10(1):1-9.
Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Annals of Pharmacotherapy. 2015 Aug;49(8):907-37.
Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clinical and translational science. 2016 Apr;9(2):89.
Esfahani K, Roudaia L, Buhlaiga NA, Del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. Current Oncology. 2020 Apr;27(s2):87-97.
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Next generation of immunotherapy for melanoma. Journal of Clinical Oncology. 2008 Jul 10;26(20):3445-55.
Beiu C, Giurcaneanu C, Grumezescu AM, Holban AM, Popa LG, Mihai MM. Nanosystems for improved targeted therapies in melanoma. Journal of clinical medicine. 2020 Jan 23;9(2):318.
Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007 Feb;445(7130):851-7.
Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted therapy in melanoma and mechanisms of resistance. International Journal of Molecular Sciences. 2020 Jun 27;21(13):4576.
Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. The oncologist. 2011 Jan;16(1):5-24.
Queirolo P, Acquati M. Targeted therapies in melanoma. Cancer treatment reviews. 2006 Nov 1;32(7):524-31.
Khan N, Khan MK, Almas an A, Singh AD, Macklis R. The evolving role of radiation therapy in the management of malignant melanoma. International Journal of Radiation Oncology* Biology* Physics. 2011 Jul 1;80(3):645-54.
Barker CA, Postop MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. International Journal of Radiation Oncology* Biology* Physics. 2014 Apr 1;88(5):986-97.
Finger PT. Radiation therapy for choroidal melanoma. Survey of ophthalmology. 1997 Nov 1;42(3):215-32.
Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. The Cancer Journal. 2012 Mar 1;18(2):203-7.
Goldschmidt H, Breneman JC, Breneman DL. Ionizing radiation therapy in dermatology. Journal of the American Academy of Dermatology. 1994 Feb 1;30(2):157-82.
Krausz AE, H William Higgins II, Etzkorn J, Sobanko J, Shin T, Giordano C, McMurray SL, Golda N, Maher IA, Leitenberger JJ, Bar A. Systematic review of technical variations for Mohs micrographic surgery for melanoma. Dermatologic Surgery. 2021 Dec 1;47(12):1539-44.
Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Annals of oncology. 2009 Aug 1;20:vi22-9.
Beaulieu D, Fathi R, Srivastava D, Nijhawan RI. Current perspectives on Mohs micrographic surgery for melanoma. Clinical, Cosmetic and Investigational Dermatology. 2018;11:309.
Kaufmann R. Surgical management of primary melanoma: Clinical dermatology• Review article. Clinical and Experimental Dermatology: Clinical dermatology. 2000 Nov;25(6):476-81.
Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Current opinion in oncology. 2004 Mar 1;16(2):155-60.